Healthcare innovation doesn’t fail because of a lack of science.
It fails when governance, execution, and incentives break down.
A conversation with George Syrmalis on governance, capital discipline, and where AI actually creates value in life sciences.
In a new episode of Analyzing Healthcare, Roy Bejarano, CEO & Co-Founder of SCALE Healthcare, speaks with George Syrmalis, Founder & CEO of Bioscience Equity Partners, to unpack how early-stage biotech, medtech, and digital health investments are actually evaluated — and why many markets struggle to attract serious global capital.
Watch the full video below:
Drawing on decades of experience as a physician, biotech founder, and global investor, George explains why execution quality, intellectual property, regulatory clarity, and governance structures matter far more than geography — and why much of today’s “AI in biotech” narrative collapses under real diligence.
Dr. George Syrmalis is a physician-scientist, entrepreneur, and global healthcare investor. He is the Founder & CEO of Bioscience Equity Partners, a specialist investment bank and fund manager focused on early-stage biotech, medtech, and digital health ventures.
With decades of experience bridging scientific innovation and capital markets, his work emphasizes rigorous science, governance discipline, and strategic execution to help life sciences technologies advance from discovery through financing and public markets.
than geography — and why much of today’s “AI in biotech” narrative collapses under real diligence.
What This Conversation Explores:
– Where AI is meaningfully improving drug discovery and research workflows
– Why most “AI biotech” pitches fail under investor scrutiny
– The difference between real scientific innovation and AI labeling
– How governance and IP structures determine early-stage success
– FDA clarity versus lower-cost regulators abroad
– Big Pharma’s looming patent cliff and its impact on M&A and deal flow
– Why patience still matters in early-stage biotech despite market pressure
